OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

NewsGuard 100/100 Score

OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva® (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer (NSCLC) who have undergone surgery and have EGFR-positive tumors. RADIANT is an international, randomized, double-blinded, placebo-controlled Phase III study that has reached its enrollment goal of 945 patients. The primary objective of the study is to determine whether the targeted therapy Tarceva prolongs disease-free survival when given as an adjuvant therapy. This is defined as a cancer treatment that is given after the primary treatment, which is typically surgery or surgery and chemotherapy in this group of NSCLC patients, to lower the risk of the cancer coming back.

“The study has received considerable interest from both investigators and patients and we look forward to the potential for interim results in 2012 and final results in 2013-2014.”

"We believe an oral therapy like Tarceva can be a valuable addition to the treatment paradigm by extending the disease-free survival of patients with Stage Ib-IIIa NSCLC," said Colin Goddard, Ph.D., Chief Executive Officer of OSI Pharmaceuticals. "The study has received considerable interest from both investigators and patients and we look forward to the potential for interim results in 2012 and final results in 2013-2014."

Source:

OSI Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions